

Regional Project Concept Template (Category A)

The information contained in this template should be uploaded to the PCMF IT platform by the Chair of the relevant regional cooperative agreement or the NLO of the Member State submitting the concept by **31 May 2012** at the latest. Based on this information the IAEA will assess whether this project concept is in line with the TC quality criteria and requirements. Concepts positively appraised will be further developed into full project documents during the design phase.

Region:	RCA (ASIA)		
Regional/Cooperative agreement (if applicable)	RCA	Priority no. given by regional/cooperative agreement (for concepts proposed under the auspices of regional cooperative agreements)	
Title	Therapeutic applications in Nuclear Medicine		
Field of activity	Nuclear Medicine		
Regional project category¹	<input type="checkbox"/> Transnational <input type="checkbox"/> Regional standard setting <input checked="" type="checkbox"/> Capacity building for developing countries <input type="checkbox"/> Joint TC activities with a regional entity		
Names and contact details of project counterparts and counterpart institutions (starting with the main counterpart)	<p>Dr. Muhammad Asif Rafique (Nuclear Physician, Principal Medical Officer) Nuclear Medicine, Oncology and Radiotherapy Institute (NORI), G-8/3, P.O.Box No. 1590, Islamabad, Pakistan. Tel. No. 92-51-9260611, Fax No. 92-51-9260616, Email: nori@noripaec.pk</p> <p>Dr. Shazia Fatima (Nuclear Physician, Principal Medical Officer) Nuclear Medicine, Oncology and Radiotherapy Institute (NORI), G-8/3, P.O.Box No. 1590, Islamabad, Pakistan. Tel. No. 92-51-9260611, Fax No. 92-51-9260616, Email: nori@noripaec.pk</p> <p>Mr. Naseer Ahmed (Radiopharmacist) Nuclear Medicine, Oncology and Radiotherapy Institute (NORI), G-8/3, P.O.Box No. 1590, Islamabad, Pakistan. Tel. No. 92-51-9260611, Fax No. 92-51-9260616, Email: nori@noripaec.pk</p>		
Analysis of regional Gap / Problems/needs	<p>Therapy of various diseases including cancers using radiolabelled pharmaceuticals can be carried out in a Nuclear Medicine facility equipped with a good radiopharmacy, imaging equipment (e.g. SPECT/CT, PET/CT, PET/MRI, etc) and having trained man-power. Current facilities for effective management of various cancers include preparation and administration of radiolabelled peptides and antibodies (fragments) which are quite successful in disease monitoring as well therapy. Such modalities virtually are non-existent in this region and there is desire need for facilities to develop new labelled radiopharmaceuticals, their administration to human for disease monitoring (imaging) as well as therapy.</p>		
Why should it be a regional project?	<p>All components (radiopharmacy, isotopes, pharmaceuticals, various involved equipments and expertise) are not available at National level in any country of the region and it will be better to manage it at regional level so that all countries can be benefitted.</p>		
Stakeholder analysis and partnerships	<p>Due to non-availability of manufacturing, imaging and therapeutic facilities using radiolabelled peptides, antibodies, Ga-68, etc and expertise cancer patients are deprived of these treatments.</p>		

¹ See the document entitled "Policy and Procedures for TC Regional Projects" at: http://pcmf.iaea.org/DesktopModules/PCMF/docs/2014_15_Docs/notes/Regional_TC_Project_Policy.pdf.

Overall objective (or developmental objective)	Overall objective is development of facilities and expertise for development and utilization of new radiolabelled pharmaceuticals for disease monitoring and therapy in Nuclear Medicine facilities of the region			
Analysis of objectives	Synthesis of radiolabelled peptides, antibodies and other beta-emitting radiopharmaceuticals for therapy Availability of Ga-68, SPECT/CT, PET/CT, PET/MRI for imaging			
Role of nuclear technology and the IAEA	Nuclear Medicine experts and IAEA can come together to promote peaceful uses of Nuclear Technology in human life in the developing countries of ASIA region			
Project duration	4 years			
Requirements for participation	Human resource and financial support			
Participating Member States	<p><i>Pakistan:</i></p> <p style="text-align: right;"><input type="checkbox"/> Resource (providing expertise) √Target (receiving expertise)</p> <p><i>China/Korea:</i></p> <p style="text-align: right;">√Resource (providing expertise) <input type="checkbox"/> Target (receiving expertise)</p> <p><i>UK/Germany/USA:</i></p> <p style="text-align: right;">√Resource (providing expertise) <input type="checkbox"/> Target (receiving expertise)</p>			
Funding and project budget	<i>Provide an estimate of the total project costs and the funding expected from each stakeholder:</i>			
		Euro	Comment	
	<i>Government cost-sharing</i>	NIL		
	<i>Counterpart institution(s)</i>	PINSTECH		
	<i>Other partners</i>			
	<i>IAEA Technical Cooperation Fund (TCF):</i>	<i>Fellowships / Scientific visits / Training courses / Workshops</i>	15000 Euro	
		<i>Experts</i>	10000 Euro	
		<i>Equipment & Radiopharmaceuticals</i>	100000 Euro	
	TOTAL	125000 Euro		